Thai Editorial Urges Tough Stance On CL Issue With U.S.
This article was originally published in PharmAsia News
The Bangkok Post was sharply critical in an editorial of the U.S. position on Thailand's unsettled compulsory license policy. The newspaper urged the Thai government to "take a strong, unalterable stance on this vital issue," one in favor of imposing compulsory licensing for drugs for the sake of 64 million Thais. "Care of Thais comes before patent law," it said, and accused the U.S. government of escalating "its imagined dispute with Thailand far out of proportion." Otherwise, it said, there is little difference between the two countries on intellectual property enforcement. (Click here for more
You may also be interested in...
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.